openPR Logo
Press release

Professional Pharmaceutical Intermediates Supplier Huateng Pharma Has Its Own Factory

09-24-2020 11:28 AM CET | Health & Medicine

Press release from: Hunan Huateng Pharmaceutical Co. Ltd.

Professional Pharmaceutical Intermediates Supplier Huateng

Hunan Huateng Pharmaceutical Co., Ltd. is a leading and professional manufacturer which can provide PEG derivatives, biochemical reagents, pharmaceutical intermediates, APIs, Vitamin D Derivatives and targeted anti-tumor drugs.

Today, Huateng Pharma has an R&D base of 5,000 square meters and a smart pharmaceutical industrial park with an investment of RMB 300 million and an industrial park of 34,000 square meters that has been completed and will be put into operation soon. The park integrates basic technology development, medical research, and achievement transformation. After it is fully put into production, it can achieve annual sales revenue of RMB 1 billion.

In addition, Huateng Pharma has established Huateng Pharmaceutical Research Institute to capture cutting-edge industry information and technology, enhance its R&D and production capabilities for high-end generic drugs and innovative drugs, and promote the industrialization of scientific research results. At present, we have independently developed several thousand kinds of products and have more than 300 invention patents.

Huateng Pharma has large scale manufacturing capabilities at our modern facility. It is equipped with more than 800 sets of state-of-the-art facilities and management systems based on the general trend of intelligent manufacturing, including production equipment such as reactors, cryostats, rectifying towers, centrifuges, DCS automatic control system, online monitoring equipment, as well as R&D analysis and testing equipment such as ICP-MS, HPLC, GC, LPSA, etc.

Huateng Pharma always insists on technological innovation as its core competitiveness. And the company is committed to providing high-quality pharmaceutical products and services to customers around the world with the belief of “Strive for the Human Health".

Hunan Huateng Pharmaceutical Co. Ltd.
Add: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China
zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818
Website: https://en.huatengsci.com/
Email:sales@huatengusa.com

Human Huateng Pharmaceutical Co., Ltd. is a leading and professional manufacturer which can provide PEG derivatives, biochemical reagents, pharmaceutical intermediates, APIs, Vitamin D Derivatives and targeted anti-tumor drugs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Professional Pharmaceutical Intermediates Supplier Huateng Pharma Has Its Own Factory here

News-ID: 2140958 • Views:

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Supplies Minoxidil Intermediate 2,4-Diamino-6-chloropyrimidine (CAS NO.156-83-2)
Huateng Pharma Supplies Minoxidil Intermediate 2,4-Diamino-6-chloropyrimidine (C …
Minoxidil was first introduced by Upjohn Company of the United States, and was first used as an oral drug for the treatment of refractory hypertension in the 1970s. In later clinical applications, doctors observed hair regrowth and generalized excessive hair in balding patients, which led to the development of minoxidil preparations. Minoxidil can increase local blood supply, stimulate the proliferation and differentiation of hair follicle epithelial cells, so as to promote
Huateng Pharma Supplies Anti-diabetic API Intermediates With Huge Stock
Huateng Pharma Supplies Anti-diabetic API Intermediates With Huge Stock
Diabetes is a serious chronic disease characterized by elevated blood sugar concentrations associated with the effects of abnormal beta cell biology on insulin action. Diabetes occurs when the pancreas does not produce enough insulin or the body does not use the insulin it does produce efficiently. The most common forms of diabetes are type 1 diabetes and type 2 diabetes. Type 1 diabetes is characterized by insufficient insulin production and
Huateng Pharma Supplies Some Intermediates of CDK4/6 Inhibitors for Treatment of Advanced Breast Cancer
Huateng Pharma Supplies Some Intermediates of CDK4/6 Inhibitors for Treatment of …
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer - that is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally. The majority
ADC Drugs For HER2 Positive Breast Cancer
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis. Although more drug

All 5 Releases


More Releases for Pharma

Antiemetics Market Size 2022 Analysis by Top Key Players| Acacia Pharma Group Pl …
Antiemetics Market research added by the Absolute Markets Insights, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavors. Access the PDF sample of the report@
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the
Indometacin Market Top Key Manufacturers Aidarex, Ratiopharm, Merck, Xinhua Phar …
The Global Indometacin Market is a nonsteroidal anti-inflammatory drug commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. The demand for nonsteroidal anti-inflammatory drug has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted. However, such as side effects of anti-inflammatory drugs and patent expiry issues may hamper the market growth in the review period. For More Info, Get Sample Report
Hydroxycarbamide Market Study Report 2019| Taj Pharma, Beijing Jialin Pharma, Qi …
Los Angeles, United State, June 11, 2019, - The global Hydroxycarbamide market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Hydroxycarbamide
TIGLUTIK Market 2019: Top Players are Sanofi, Mylan Pharma, Apotex, Glemark Gene …
TIGLUTIK Market 2019 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry. Get Sample Copy of this Report@ https://www.researchreportsworld.com/enquiry/request-sample/13709986 Global TIGLUTIK market 2019 research provides a basic overview of the industry including definitions, classifications, applications